Inhibition of guinea pig skin allergic reactions by nonpeptide bradykinin B2 receptor antagonist FR173657

International Archives of Allergy and Immunology

Volumn 116, Issue 4, 1998, Pages 278-283

  Mori, Takeshi ^a,b   Imamura, Takahisa ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Allergy; Anaphylactic reaction; Antagonist; Arthus reaction; B2 receptor; Bradykinin; Guinea pig; Vascular permeability

Indexed keywords

2,4 DINITROPHENOL; 3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; BOVINE SERUM ALBUMIN; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; FREUND ADJUVANT; KININ; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; GUINEA PIG; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN ALLERGY; SKIN SENSITIZATION;

ANIMALS; DINITROPHENOLS; GUINEA PIGS; HUMANS; HYPERSENSITIVITY; QUINOLINES; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; SERUM ALBUMIN, BOVINE; SKIN;

EID: 0031857234     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000023956     Document Type: Article

References (40)

1. Siraganian RP: Mechanism of IgE-mediated hypersensitivity: in Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW (eds): Allergy, ed 4. St Louis, Mosby, 1993, vol 1, pp 105-134.
2. Ranadive NS, Movat HZ: Tissue injury and inflammation induced by immune complexes: in Movat HZ (ed): Inflammation, Immunity and Hypersensitivity. New York, Harper & Row, 1979, pp 409-443.
3. Holgate ST, Robinson C, Church MK: Mediators of immediate hypersensitivity; in Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW (eds): Allergy, ed 4. St Louis, Mosby 1993, vol 1, pp 267-301.
4. Garcia-Leme J: Bradykinin system; in Vane JR, Ferreira SH (eds): Handbook of Experimental Pharmacology. Inflammation. Berlin, Springer, 1978, vol 50, pp 464-522.
5. Marceau F, Lussier A, Regoli D, Giroud JP: Pharmacology of kinins: Their relevance to tissue injury and inflammation. Gen Pharmacol 1983;14:209-229.
6. Varonier HS, Panzani R: The effect of inhalations of bradykinin on healthy and atopic (asthmatic) children. Int Arch Allergy Appl Immunol 1968;34:293-296.
7. Fuller RW, Dixon CMS, Cuss FMC, Barnes PJ: Bradykinin-induced bronchoconstriction in humans: Mode of action. Am Rev Respir Dis 1987;135:176-180.
8. Pround D, Reynolds CJ, Lacapra S, Kagey-Sobotka A, Lichteinstein LM, Naclerio RM: Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis 1988;137:613-616.
9. Baraniuk JN, Silver PB, Kaliner MA, Barnes PJ: Perennial rhinitis subjects have altered vascular, glandular and neural responses to bradykinin nasal provocation. Int Arch Allergy Immunol 1994;103:202-208.
10. Russell MT II, Winkelmann RK, Gleich GJ: Release of kinins from site of wheal-and-flare allergic skin reactions. Int Arch Allergy Appl Immunol 1970;39:616-624.
11. Proud D, Togias A, Naclerio RM, Crush SA: Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest 1983;72:1678-1685.
12. Svensson C, Andersson M, Persson CGA, Venge P, Alkner U, Pipkorn U: Albumin, bradykinin, and eosinophil cationic protein on the nasal mucosal surface in patients with hay fever during natural allergen exposure. J Allergy Clin Immunol 1990;85:823-833.
13. Proud D, Sweet J, Stein P, Settipane RA, Kagey-Sobotka A, Fiedlaender MH, Lichtenstein LM: Inflammatory mediator release on conjunctival provocation of allergic with allergen. J Allergy Clin Immunol 1990;85:896-905.
14. Regoli D, Barabé J: Pharmacology of bradykinin and related peptides. Pharmacol Rev 1980;32:1-46.
15. Hess JF, Borkowski JA, Young GS, Strader CD, Ransom RW: Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 1992;184:260-268.
16. 1 bradykinin receptor. J Biol Chem 1994;269:21583-21586.
17. 9]-bradykinin in atopic rhinitic and normal volunteers. J Physiol (Lond) 1991;437:557.
18. 2 receptor antagonist, FR173657. Br J Pharmacol 1997;120: 617-624.
19. Eisen HN, Garsten ME, Belman S: Studies of hypersensitivity to low molecular weight substances. J Immunol 1954;73:296-308.
20. Granziano F, Haley C, Gundersen L, Askenase PW: IgE antibody production in guinea pigs treated with cyclophosphamide. J Immunol 1981;127:1067-1070.
21. Levine BB, Vaz NM: Effect of combinations of inbred strain, antigen, and antigen dose on immune responsiveness and reagin production in the mouse. Int Arch Allergy Appl Immunol 1970;39:156-171.
22. Imamura T, Kambara T: Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin. Inflammation 1992;16:169-177.
23. Udaka K, Takeuchi Y, Movat HZ: Simple method for quantilation of enhanced vascular permeability. Proc Soc Exp Biol Med 1970; 133:1384-1387.
24. Schachter M, Uchida Y, Longridge DJ, Labedz T, Whalley ET, Vavrek RJ, Stewart JM: New synthetic antagonists of bradykinin. Br J Pharmacol 1987;92:851-855.
25. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, König W, Knolle J, Schölkens BA: Hoe 140 a new potent and long-acting bradykinin-antagonist: In vitro studies. Br J Pharmacol 1991;102:769-773.
26. Imamura T, Pike RN, Potempa J, Travis J: Pathogenesis of periodontitis: A major arginine-specific cysteine proteinase from Porphyromonas gingivalis induces vascular permeability enhancement through activation of the kallikrein/kinin pathway. J Clin Invest 1994; 94:361-367.
27. Abraham WM: The potential role of bradykinin antagonist in the treatment of asthma. Agents Actions Suppl 1992;38 (pt 3):439-449.
28. 2 bradykinin receptors. FASEB J 1989;3:2019-2025.
29. 2 receptors and BK3 receptors. Br J Pharmacol 1991;102:785-787.
30. Johnson AR, Hugh TE, Müller-Eberhard EJ: Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 1975;28:1067-1080.
31. Ramos BF, Zhang Y, Angkachatchai V, Jakschik BA: Mast cell mediators regulate vascular permeability changes in Arthus reaction. J Pharmacol Exp Ther 1992;262:559-565.
32. Spector WG, Willoughby DA: Vasoactive amines in acute inflammation. Ann Ny Acad Sci 1964;116:839-846.
33. Imamura T, Duhin A, Moore W, Tanaka R, Travis J: Induction of vascular permeability enhancement by human tryptase: Dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab Invest 1996;74:861-870.
34. Schwartz LB, Lewis RA, Seldin D, Austen KF: Acid hydrases and tryptase from secretory granules of dispersed human lung mast cells. J Immunol 1981;126:1290-1294.
35. Naclerio RM, Proud D, Togias AG, Adkinson NF, Meyers D, Kagey-Sobotka A, Flaut M, Norman P, Lichtenstein LM: Inflammatory mediators in late antigen-induced rhinits. N Engl J Med 1985;313:65-70.
36. Warren JS, Mandel DM, Johnson KJ, Ward PA: Evidence for the role of platelet-activating in immune complex vasculitis in the rat. J Clin Invest 1989;83:669-678.
37. Okamoto H, Iwahisa Y, Terasawa M: Suppression of the Arthus reaction by y-224180, a potent and specific antagonist of platelet-activating factor. Agents Actions 1992;35:149-158.
38. Teixeira MM, Fairbairn SM, Norman KE, Williams TJ, Rossi AG, Hellewell PG: Studies on the mechanisms involved in the inflammatory response in a reversed passive Arthus reaction in guinea pig skin: Contribution of neutrophils and endogenous mediators. Br J Pharmacol 1994;113:1363-1371.
39. Hayashi H, Yoshinaga M, Koono M, Miyoshi H, Matsumura M: Endogenous permeability factors and their inhibitors affecting vascular permeability in cutaneous Arthus reactions and thermal injury. Br J Exp Pathol 1964;45:419-435.
40. Sawutz DG, Salvino JM, Dolle RE, Casiano F, Ward SJ, Houck WT, Faunce DM, Douty BD, Baizman E, Awad MMA, Marceau F, Seoane PR: The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist. Proc Natl Acad Sci USA 1994;91:4693-4697.